iData Pharmaceutical News 09-01-2017: Company Acquisitions and FDA Approvals for Gene Therapy

Register to receive a free North American Market Report Suite for Immunology Drugs report synopsis and brochure

Oncodesign Announces the Acquisition of Bertin Pharma’s Pharmaceutical and Biotech Services Businesses

Oncodesign a biopharma company dedicated to the precision medicine, is announcing an agreement to acquire Bertin Pharma’s metabolism, pharmacokinetics, bioanalysis and translational medicine service activities. The agreement becomes unconditional today.

This deal covers the transfer of a team of 46 highly qualified multidisciplinary employees to support the proprietary or third-party discovery and development of new drugs in areas such as immunology and infectious diseases. The scope of the transfer includes capacity to study the absorption, distribution, metabolism and excretion of therapeutic molecules (ADME), regulated bioanalysis, and centralized biobanking to manage biological samples, both with and without the risk of infection.

For more information, please visit the official press release

FDA approval brings first gene therapy to the United States

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”

Kymriah, a cell-based gene therapy, is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

For more information, please visit the official FDA Press Announcements section

For Further Information
The Immunology Drugs Market Report Suite covers reports on the following markets: Rheumatoid Arthritis Treatment, Crohn’s Disease Treatment, Psoriasis Treatment, Ankylosing Spondylitis Treatment and Ulcerative Colitis Treatment.

The iData report series on immunology drugs covers the U.S., Canada, Brazil, Russia, India, China, Japan, U.K. Germany, Spain, Italy and France. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about immunology drug market data, register online or email us at for a North American Market Report Suite for Immunology Drugs brochure and synopsis.

Leave a Reply